|
1
|
Global Burden of Disease Cancer
Collaboration. Fitzmaurice C, Allen C, Barber RM, Barregard L,
Bhutta ZA, Brenner H, Dicker DJ, Chimed-Orchir O, Dandona R, et al:
Global, regional, and national cancer incidence, mortality, years
of life lost, years lived with disability, and disability-adjusted
life-years for 32 cancer groups, 1990 to 2015: A systematic
analysis for the global burden of disease study. JAMA Oncol.
3:524–548. 2017.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Fornaro L, Vasile E, Aprile G, Goetze TO,
Vivaldi C, Falcone A and Al-Batran SE: Locally advanced
gastro-oesophageal cancer: Recent therapeutic advances and research
directions. Cancer Treat Rev. 69:90–100. 2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Gambardella V and Cervantes A: Precision
medicine in the adjuvant treatment of gastric cancer. Lancet Oncol.
19:583–584. 2018.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Wanger TM, Dewitt S, Collins A, Maitland
NJ, Poghosyan Z and Knauper V: Differential regulation of TROP2
release by PKC isoforms through vesicles and ADAM17. Cell Signal.
27:1325–1335. 2015.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Cubas R, Li M, Chen C and Yao Q: Trop2: A
possible therapeutic target for late stage epithelial carcinomas.
Biochim Biophys Acta. 1796:309–314. 2009.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Vidmar T, Pavsic M and Lenarcic B:
Biochemical and preliminary X-ray characterization of the
tumor-associated calcium signal transducer 2 (Trop2) ectodomain.
Protein Expr Purif. 91:69–76. 2013.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Huang H, Groth J, Sossey-Alaoui K,
Hawthorn L, Beall S and Geradts J: Aberrant expression of novel and
previously described cell membrane markers in human breast cancer
cell lines and tumors. Clin Cancer Res. 11:4357–4364.
2005.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Shvartsur A and Bonavida B: Trop2 and its
overexpression in cancers: Regulation and clinical/therapeutic
implications. Genes Cancer. 6:84–105. 2015.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Guerra E, Trerotola M, Dell' Arciprete R,
Bonasera V, Palombo B, El-Sewedy T, Ciccimarra T, Crescenzi C,
Lorenzini F, Rossi C, et al: A bicistronic CYCLIN D1-TROP2 mRNA
chimera demonstrates a novel oncogenic mechanism in human cancer.
Cancer Res. 68:8113–8121. 2008.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Lin JC, Wu YY, Wu JY, Lin TC, Wu CT, Chang
YL, Jou YS, Hong TM and Yang PC: TROP2 is epigenetically
inactivated and modulates IGF-1R signalling in lung adenocarcinoma.
EMBO Mol Med. 4:472–485. 2012.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Zhao W, Zhu H, Zhang S, Yong H, Wang W,
Zhou Y, Wang B, Wen J, Qiu Z, Ding G, et al: Trop2 is overexpressed
in gastric cancer and predicts poor prognosis. Oncotarget.
7:6136–6145. 2016.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Mühlmann G, Spizzo G, Gostner J, Zitt M,
Maier H, Moser P, Gastl G, Zitt M, Müller HM, Margreiter R, et al:
TROP2 expression as prognostic marker for gastric carcinoma. J Clin
Pathol. 62:152–158. 2009.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Fong D, Moser P, Krammel C, Gostner JM,
Margreiter R, Mitterer M, Gastl G and Spizzo G: High expression of
TROP2 correlates with poor prognosis in pancreatic cancer. Br J
Cancer. 99:1290–1295. 2008.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Fong D, Spizzo G, Gostner JM, Gastl G,
Moser P, Krammel C, Gerhard S, Rasse M and Laimer K: TROP2: A novel
prognostic marker in squamous cell carcinoma of the oral cavity.
Mod Pathol. 21:186–191. 2008.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Fang YJ, Lu ZH, Wang GQ, Pan ZZ, Zhou ZW,
Yun JP, Zhang MF and Wan DS: Elevated expressions of MMP7, TROP2,
and survivin are associated with survival, disease recurrence, and
liver metastasis of colon cancer. Int J Colorectal Dis. 24:875–884.
2009.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Bignotti E, Todeschini P, Calza S,
Falchetti M, Ravanini M, Tassi RA, Ravaggi A, Bandiera E, Romani C,
Zanotti L, et al: Trop-2 overexpression as an independent marker
for poor overall survival in ovarian carcinoma patients. Eur J
Cancer. 46:944–953. 2010.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Sin STK, Li Y, Liu M, Ma S and Guan XY:
TROP-2 exhibits tumor suppressive functions in cervical cancer by
dual inhibition of IGF-1R and ALK signaling. Gynecol Oncol.
152:185–193. 2019.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Zhang K, Jones L, Lim S, Maher CA, Adkins
D, Lewis J, Kimple RJ, Fertig EJ, Chung CH, Van Tine BA, et al:
Loss of Trop2 causes ErbB3 activation through a
neuregulin-1-dependent mechanism in the mesenchymal subtype of
HNSCC. Oncotarget. 5:9281–9294. 2014.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Mori Y, Akita K, Ojima K, Iwamoto S,
Yamashita T, Morii E and Nakada H: Trophoblast cell surface antigen
2 (Trop-2) phosphorylation by protein kinase C α/δ (PKC α/δ)
enhances cell motility. J Biol Chem. 294:11513–11524.
2019.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Stoyanova T, Goldstein AS, Cai H, Drake
JM, Huang J and Witte ON: Regulated proteolysis of Trop2 drives
epithelial hyperplasia and stem cell self-renewal via β-catenin
signaling. Genes Dev. 26:2271–2285. 2012.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Soini Y, Tommola S, Helin H and
Martikainen P: Claudins 1, 3, 4 and 5 in gastric carcinoma, loss of
claudin expression associates with the diffuse subtype. Virchows
Arch. 448:52–58. 2006.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Stanculescu D, Margaritescu C, Stepan A
and Mitrut AO: E-cadherin in gastric carcinomas related to
histological prognostic parameters. Rom J Morphol Embryol. 52
(Suppl 3):S1107–S1112. 2011.PubMed/NCBI
|
|
23
|
Larsson O, Girnita A and Girnita L: Role
of insulin-like growth factor 1 receptor signalling in cancer. Br J
Cancer. 92:2097–2101. 2005.PubMed/NCBI
|
|
24
|
Rosenzweig SA and Atreya HS: Defining the
pathway to insulin-like growth factor system targeting in cancer.
Biochem Pharmacol. 80:1115–1124. 2010.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Chiarle R, Voena C, Ambrogio C, Piva R and
Inghirami G: The anaplastic lymphoma kinase in the pathogenesis of
cancer. Nat Rev Cancer. 8:11–23. 2008.PubMed/NCBI View
Article : Google Scholar
|
|
26
|
Bardia A, Mayer IA, Vahdat LT, Tolaney SM,
Isakoff SJ, Diamond JR, O'Shaughnessy J, Moroose RL, Santin AD,
Abramson VG, et al: Sacituzumab govitecan-hziy in refractory
metastatic triple-negative breast cancer. N Engl J Med.
380:741–751. 2019.PubMed/NCBI View Article : Google Scholar
|
